首页> 外文OA文献 >Inside Cover: Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities (ChemMedChem 8/2016)

【2h】

Inside Cover: Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities (ChemMedChem 8/2016)

机译：内部封面：撤防亲电子弹头：在规避药代动力学负债的同时保持酪氨酸激酶抑制剂（TKI）抑制剂（TKI）的效力（ChemMedchem 8/2016）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Ahmed M. Ali; Rodolfo F. Gómez-Biagi; David A. Rosa; Ping-Shan Lai; William L. Heaton; Ji Sung Park; Anna M. Eiring; Nadeem A. Vellore; Elvin D. de Araujo; Dan P. Ball; Andrew E. Shouksmith; Ami B. Patel; Michael W. Deininger; Thomas OHare; Patrick T. Gunning;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities [J] . Ali Ahmed M., Gomez-Biagi Rodolfo F., Rosa David A., ChemMedChem . 2016,第8期

机译：解除亲电子战斗部的武装：避免酪氨酸激酶抑制剂（TKI）的抗CML品系保持药代动力学责任。
2. Factors Affecting Survival Outcomes in Patients with Blast Phase CML (CML-BP) in the Tyrosine Kinase Inhibitor (TKI) Era: A Cohort Study of 498 Patients [J] . Jain Preetesh, Kantarjian Hagop M., Jabbour Elias J., Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：酪氨酸激酶抑制剂（TKI）时代的高发期CML（CML-BP）患者生存结果的影响因素：一项498名患者的队列研究
3. Factors Affecting Survival Outcomes in Patients with Blast Phase CML (CML-BP) in the Tyrosine Kinase Inhibitor (TKI) Era: A Cohort Study of 498 Patients [J] . Jain Preetesh, Kantarjian Hagop M., Jabbour Elias J., Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：酪氨酸激酶抑制剂（TKI）时代的高发期CML（CML-BP）患者生存结果的影响因素：一项498名患者的队列研究
4. Disarming an electrophilic warhead: Retaining potency in Tyrosine Kinase Inhibitor (TKI)-resistant CML lines while circumventing pharmacokinetic liabilities [O] . Prof. Ahmed M. Ali, Dr. Rodolfo F. Gómez-Biagi, Dr. David A. Rosa, -1

机译：解除亲电子战斗部的武装：保留抗酪氨酸激酶抑制剂（TKI）的CML品系的效力同时规避药代动力学责任
5. PCN63 Increasing Burden of Tyrosine Kinase Inhibitor (TKI) Treatment Failure with Later Lines of Therapy (LOT) in Chronic Myeloid Leukemia (CML): A Real World Retrospective Database Analysis [O] . Chen Y.J., Huang H., Divino V., 2014

机译：慢性粒细胞白血病（CML）中PCN63酪氨酸激酶抑制剂（TKI）治疗失败的负担增加，而后期疗法（LOT）的治疗：现实世界的回顾性数据库分析

Inside Cover: Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities (ChemMedChem 8/2016)

著录项

引文网络

相似文献

相关主题

期刊订阅